Overview of the main outcomes in breast-cancer prevention trials

Lancet

Volumn 361, Issue 9354, 2003, Pages 296-300

  Cuzick, J ^a   Powles, T ^b   Veronesi, U ^c   Forbes, J ^d   Edwards, R ^a   Ashley, S ^b   Boyle, P ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d Australian New Zealand Breast Cancer Trials Group   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGE; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FOLLOW UP; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0037464769     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12342-2     Document Type: Article

References (9)

1. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 360:2002;817-824.
2. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1387.
3. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 65:2001;125-134.
4. Powles T.J., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
5. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 352:1998;93-97.
6. Veronesi U., Maisonneuve P., Sacchini V., et al. Tamoxifen for breast cancer among hysterectomised women. Lancet. 359:2002;1122-1124.
7. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
8. Camerini T., Mariani L., de Palo G., et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol. 19:2001;1664-1670.
9. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2002;2131-2139.